Early access
Sign in
Taking peopleNo phase

Checking the Hscore for diagnosing hemophagocytosis in intensive care patients

Looks back at how well the Hscore works in intensive care patients.

Key facts

Who runs it
University Hospital, Strasbourg, France
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care
Status
Recruiting
People taking part
100 people, planned
Started
29 Aug 2025
Planned end
29 Aug 2026
Type of study
Observational
Record updated
15 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults admitted to intensive care at Hautepierre Hospital, Strasbourg, between January 1, 2014, and December 31, 2024, with blood signs of HLH. HLH is a severe overreaction of the immune system. The study looks back at existing records.

Age
18 years and older
Sex
All
Disease stage
Patients treated in the intensive care unit with at least 3 blood signs of HLH (lymphohistiocytic hemophagocytosis).
Biomarker or test result
Ferritin > 2000 ng/mL; triglycerides > 1.5 g/L; at least one low blood count: leukocytes ≤ 5000 G/L, platelets ≤ 110 G/L, or hemoglobin ≤ 9.2 g/dL.

Main reasons for not taking part

  • People who refuse to take part in the study cannot join.

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Adult patient (≥18 years old)
  • Patient admitted to the intensive care unit at Hautepierre Hospital, Strasbourg University Hospital, between January 1, 2014, and December 31, 2024
  • At least 3 biological signs of HLH:; ferritin > 2000 ng/mL; triglycerides > 1.5 g/L; at least one cytopenia (leukocytes ≤ 5000 G/L, platelets ≤ 110 G/L, hemoglobin ≤ 9.2 g/dL)

Who cannot take part

  • Refusal to participate in the study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Patients with hepatocellular insufficiency and/or cirrhosis are at risk of developing invasive fungal infections, particularly in critical care settings.

Read full original descriptionShow less

In international recommendations, voriconazole is positioned as the first-line treatment for invasive aspergillosis. However, this molecule-and the azole class of antifungals-is associated with frequent hepatic toxicity. Available since 2018, isavuconazole appears to be better tolerated in patients without pre-existing liver dysfunction.

The aim of this study is to retrospectively evaluate the validity of the hscore in intensive care and resuscitation patients.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care: Relevance of the Hscore and Search for the Best Diagnostic Markers
Plain-language title
Checking the Hscore for diagnosing hemophagocytosis in intensive care patientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
15 January 2026